Accessibility Menu
 
Maravai LifeSciences logo

Maravai LifeSciences

(NASDAQ) MRVI

Current Price$2.87
Market Cap$418.66M
Since IPO (2020)-90%
5 Year-92%
1 Year+22%
1 Month-19%

Maravai LifeSciences Financials at a Glance

Market Cap

$418.66M

Revenue (TTM)

$185.74M

Net Income (TTM)

$130.77M

EPS (TTM)

$-0.91

P/E Ratio

-3.16

Dividend

$0.00

Beta (Volatility)

1.10 (Average)

Price

$2.87

Volume

930,321.8

Open

$2.87

Previous Close

$2.88

Daily Range

$2.82 - $2.95

52-Week Range

$1.67 - $4.11

MRVI: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Maravai LifeSciences

Industry

Life Sciences Tools and Services

Employees

435

CEO

Bernd Brust

Headquarters

San Diego, CA 92121, US

MRVI Financials

Key Financial Metrics (TTM)

Gross Margin

18%

Operating Margin

-4%

Net Income Margin

-70%

Return on Equity

-49%

Return on Capital

-1%

Return on Assets

-17%

Earnings Yield

-31.65%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$418.66M

Shares Outstanding

146.38M

Volume

930.32K

Short Interest

0.00%

Avg. Volume

1.37M

Financials (TTM)

Gross Profit

$33.39M

Operating Income

$6.74M

EBITDA

$147.11M

Operating Cash Flow

$57.57M

Capital Expenditure

$13.15M

Free Cash Flow

$70.72M

Cash & ST Invst.

$216.89M

Total Debt

$35.58M

Maravai LifeSciences Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$49.87M

-11.6%

Gross Profit

$12.24M

-35.4%

Gross Margin

24.55%

N/A

Market Cap

$418.66M

N/A

Market Cap/Employee

$734.48K

N/A

Employees

570

N/A

Net Income

$35.68M

-36.5%

EBITDA

$41.72M

-101.4%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$181.31M

+433.9%

Accounts Receivable

$25.50M

-33.8%

Inventory

$0.00

-100.0%

Long Term Debt

$30.14M

-91.7%

Short Term Debt

$5.44M

-60.3%

Return on Assets

-16.97%

N/A

Return on Invested Capital

-0.93%

N/A

Free Cash Flow

$24.88M

-21.5%

Operating Cash Flow

$22.77M

-55.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DNAGinkgo Bioworks Holdings, Inc.
$5.48-7.59%
PRMEPrime Medicine, Inc.
$3.15-6.80%
LENZLENZ Therapeutics, Inc.
$8.29-1.31%
REPLReplimune Group, Inc.
$7.20-0.28%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$8.52+0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$37.89-0.02%
ONDSOndas
$8.15-0.07%
QQQInvesco QQQ Trust
$558.28-0.01%

Questions About MRVI

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.